Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021-Reference-Cited by-同舟云学术

Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021

Published:2023-01-03 Issue:1 Volume:329 Page:87
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Feldman William B.¹,Tu S. Sean²,Alhiary Rasha³,Kesselheim Aaron S.¹,Wouters Olivier J.⁴

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts

2. West Virginia University College of Law, Morgantown

3. University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania

4. Department of Health Policy, London School of Economics and Political Science, London, England

Abstract

This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2800037/jama_feldman_2023_ld_220077_1671563420.63514.pdf

Reference6 articles.

1. Tertiary patenting on drug-device combination products in the United States.;Beall;Nat Biotechnol,2018

2. Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986-2020.;Feldman;Health Aff (Millwood),2022

3. Out-of-pocket costs and prescription filling behavior of commercially insured individuals with chronic obstructive pulmonary disease.;Patel;JAMA Health Forum,2022

4. Trends in Medicare Part D inhaler spending: 2012-2018.;Feldman;Ann Am Thorac Soc,2021

5. Orange Book Transparency Act of 2020, HR 1503, 116th Cong, Pub L 116-290. Accessed July 18, 2022. https://www.congress.gov/bill/116th-congress/house-bill/1503/text?q=%7B%22search%22%3A%5B%22H.+R.+1503%22%5D%7D&r=1&s=1

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cost of drug patent expiration date errors;Nature Biotechnology;2024-07

2. Medicare Negotiation’s Drug Reformulation Problem;Annals of Internal Medicine;2024-06

3. Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly;Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation;2024

4. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists;JAMA;2023-08-15

5. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone–Salmeterol to Treat Chronic Obstructive Pulmonary Disease;Annals of Internal Medicine;2023-08